Skip to content

Mechanism of Effect of Feiyanjing Fomula on lung cancer growth and metastasis

Mechanism of Effect of Feiyanjing Fomula on lung cancer growth and metastasis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800019176
Enrollment
Unknown
Registered
2018-10-30
Start date
2018-12-01
Completion date
Unknown
Last updated
2018-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Case series:Chinese medicine lung Yan Ning prescription

Sponsors

Longhua Hospital, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) NSCLC was diagnosed by imaging, pathology and cytology; 2) according to UICC2017's Eighth Edition TNM staging standard, it was diagnosed as stage III B to IV NSCLC with inoperable treatment; 3) EGFR (-), ROS (-), ALK (-); 4) Karnofsky score was more than 80; 5) the age is 18~78 years old; the sex is not limited; 6) TCM syndrome differentiation is in line with the two deficiency of essence Qi (two asthenia of lung and kidney); 7) the expected life period is more than 4 months; 8) the end of radiotherapy and chemotherapy was more than or equal to February, and the Six Gentlemen Decoction was administered uniformly during the elution period; 9) patients understand the study and sign informed consent.

Exclusion criteria

Exclusion criteria: 1) those who do not conform to the above standards; 2) combined with severe heart, liver and kidney diseases and hematological diseases; 3) liver metastases and brain metastases were not excised; 4) severe infection; 5) take the targeted drug patients; 6) the TCM syndrome has less than two main syndromes and less than two syndromes; 7) person who did not use the prescribed medication.

Design outcomes

Primary

MeasureTime frame
Obvious effect, no effect;

Secondary

MeasureTime frame
Change of TCM symdrom;Adverse events;

Countries

China

Contacts

Public ContactDeng Haibin

Longhua Hospital, Shanghai University of Traditional Chinese Medicine

shchinall@163.com+86 021-33324000-8128

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026